Determination of sensed and paced atrial-ventricular delay in cardiac resynchronization therapy

Pacing and Clinical Electrophysiology 2024

View Full Publication

Determination of sensed and paced atrial-ventricular delay in cardiac resynchronization therapy


Alan J. Bank MD, Christopher D. Brown BA, Kevin V. Burns PhD, Katie M. Johnson BS


Abstract


Background


Optimization of atrial-ventricular delay (AVD) during atrial sensing (SAVD) and pacing (PAVD) provides the most effective cardiac resynchronization therapy (CRT). We demonstrate a novel electrocardiographic methodology for quantifying electrical synchrony and optimizing SAVD/PAVD.


Methods


We studied 40 CRT patients with LV activation delay. Atrial-sensed to RV-sensed (As-RVs) and atrial-paced to RV-sensed (Ap-RVs) intervals were measured from intracardiac electrograms (IEGM). LV-only pacing was performed over a range of SAVD/PAVD settings. Electrical dyssynchrony (cardiac resynchronization index; CRI) was measured at each setting using a multilead ECG system placed over the anterior and posterior torso. Biventricular pacing, which included multiple interventricular delays, was also conducted in a subset of 10 patients.


Results


When paced LV-only, peak CRI was similar (93 ± 5% vs. 92 ± 5%) during atrial sensing or pacing but optimal PAVD was 61 ± 31 ms greater than optimal SAVD. The difference between As-RVs and Ap-RVs intervals on IEGMs (62 ± 31 ms) was nearly identical. The slope of the correlation line (0.98) and the correlation coefficient r (0.99) comparing the 2 methods of assessing SAVD-PAVD offset were nearly 1 and the y-intercept (0.63 ms) was near 0. During simultaneous biventricular (BiV) pacing at short AVD, SAVD and PAVD programming did not affect CRI, but CRI was significantly (p < .05) lower during atrial sensing at long AVD.


Conclusion


A novel methodology for measuring electrical dyssynchrony was used to determine electrically optimal SAVD/PAVD during LV-only pacing. When BiV pacing, shorter AVDs produce better electrical synchrony.


Elevate heart failure therapy for all CRT patients.

Connect to explore engaging with Myochron on its journey to help patients, providers, and health systems elevate the standard of care, while reducing the burden of non-response.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.